Combination cancer therapy with anti-cancer agents and antibodies targeting a complex comprising non-classical hla-i and neoantigen
AssigneeAbexxa Biologics, Inc.
InventorJon Weidanz
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods and compositions for targeting a complex comprising a non-classical HLA-I and a neoantigen in cancer characterized by expression of CD94/NKG2A inhibitory receptor. Further disclosed herein are methods and compositions for combination cancer therapy.
Claims107
A method of treating cancer characterized by expression of CD94/NKG2A inhibitory receptor in an individual in need thereof, comprising administering to the individual an antibody that selectively binds to a complex comprising an HLA-E and a neoantigen.
A method of treating cancer in an individual in need thereof, comprising administering to the individual:
- (a) an antibody that selectively binds to a complex comprising a HLA-E and a neoantigen, and
- (b) an additional anti-cancer agent.
A method of inducing cell death of a cancer cell in a tumor microenvironment characterized by expression of CD94/NKG2A inhibitory receptor in an individual in need thereof, comprising administering to the individual an antibody that selectively binds to a complex comprising an HLA-E and a neoantigen, wherein the complex is expressed by the cancer cell.
A pharmaceutical composition comprising:
- (a) an antibody that selectively binds to a complex comprising a HLA-E and a neoantigen;
- (b) an additional anti-cancer agent;
- and
- (c) a pharmaceutically acceptable carrier or excipient.
Dependencies are inferred from the claim text.